Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330655 · ClinicalTrials.gov registry record · Phase 4
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
A Phase 4 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00330655 is a Phase 4 study that has completed, run by Mclean Hospital. The registered enrollment target is 15 participants.
The verdict
NCT00330655, a Phase 4 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
We hypothesize that memantine may be a safe and effective treatment for moderate to severe binge eating disorder associated with obesity. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have moderate to severe binge eating disorder and are obese will be treated with open-label memantine. Following this 12-week treatment phase, subjects may be eligible to continue into an extension phase which will last an additional 12 weeks. During the extension phase subjects will continue open-label memantine treatment.
Interventions
- DRUG memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330655
The ClinicalTrials.gov registry entry for NCT00330655 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which memantine is the first listed.
NCT00330655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330655 about?
NCT00330655 is a clinical study titled "An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder". We hypothesize that memantine may be a safe and effective treatment for moderate to severe binge eating disorder associated with obesity. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have moderate to severe binge eating disorder...
What is the current status of trial NCT00330655?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2006-05. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00330655?
The interventions under investigation include: memantine (DRUG).
Who is sponsoring clinical trial NCT00330655?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.